HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Gene therapy for ADA-SCID, the first marketing approval of an ex vivo gene therapy in Europe: paving the road for the next generation of advanced therapy medicinal products.

AuthorsAlessandro Aiuti, Maria Grazia Roncarolo, Luigi Naldini
JournalEMBO molecular medicine (EMBO Mol Med) Vol. 9 Issue 6 Pg. 737-740 (06 2017) ISSN: 1757-4684 [Electronic] England
PMID28396566 (Publication Type: Journal Article)
Chemical References
  • ADA protein, human
  • Adenosine Deaminase
Topics
  • Adenosine Deaminase (deficiency, genetics)
  • Agammaglobulinemia (genetics, therapy)
  • Child
  • Europe
  • Genetic Therapy
  • Genetic Vectors (therapeutic use)
  • Hematopoietic Stem Cell Transplantation
  • Humans
  • Severe Combined Immunodeficiency (genetics, therapy)
  • Transplantation, Autologous

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: